BILL ANALYSIS

HR8794

NEUTRAL

FED UP with Bleeding Disorders Act of 2026

HR8794 (FED UP with Bleeding Disorders Act of 2026) has been assessed with a neutral outlook for investors. The primary sectors impacted are Healthcare. View the full bill text on Congress.gov.

neutral

Market Sentiment

Affected Stocks

Sectors Impacted

Key Takeaways for Investors

HR 8794 is a procedural authorization bill with no appropriated funds—zero direct revenue impact on any public company.

The bill targets HHS research and awareness initiatives, not procurement or tax incentives that would benefit specific firms.

Early-stage legislation with limited sponsorship and no companion bill in the Senate; passage probability is low in the 119th Congress.

How HR8794 Affects the Market

No market implications. The bill does not affect any publicly traded company's revenue, costs, or competitive position. The healthcare sector is not impacted by this procedural authorization. Investors should focus on bills with authorized funding, direct procurement, or regulatory changes that alter company economics.

Bill Details

Metric	Value
Bill Number	HR8794
Market Sentiment	neutral
Event Date	May 13, 2026
Affected Sectors	Healthcare
Affected Stocks	N/A
Source	View on Congress.gov →

Summary

HR 8794, the FED UP with Bleeding Disorders Act, is an early-stage bill referred to committee with no authorized funding. It mandates an HHS interagency review and research initiatives for bleeding disorders in underserved populations. No direct revenue impact on publicly traded companies is identifiable from the bill text.

Full AI Market Analysis

The FED UP with Bleeding Disorders Act of 2026 was introduced on May 13, 2026, and referred to the House Committee on Energy and Commerce. It is in the earliest legislative stage with no hearings or markups scheduled. The bill directs the Secretary of Health and Human Services to conduct an interagency review and establish initiatives focused on bleeding disorders in underserved populations, particularly women. It does not authorize any specific dollar amount for appropriations; any future funding would require a separate appropriations bill. The bill's findings cite economic costs of heavy menstrual bleeding ($1B direct, $12B indirect annually) but do not create a direct funding stream or procurement program. No publicly traded companies are named or directly affected by the bill's provisions. The legislative path requires committee action, House passage, Senate passage, and presidential signature—a multi-year process with low probability in the current session. The bill's sponsors include a junior House member (Rep. Julie Johnson, D-TX) with only two cosponsors, indicating limited bipartisan momentum. Without authorized funding or a regulatory mandate targeting specific industries, the market impact is negligible.